IthaMaps

Welcome to IthaMaps

IthaMaps is a global epidemiology database of heamoglobinopathies, illustrating published data on a dynamic global to regional map. Country-specific information on haemoglobinopathy-related policies, prevalence, incidence and overall disease burden is given, including relative allele frequencies of specific globin mutations in each country and/or region, dynamically linked to corresponding IthaGenes entries.

IthaMaps content was supported by partnership with the HVP Global Globin 2020 Challenge

Search

Search Country:		OR	Search for:		Show organisations

Healthcare information:
Major haemoglobinopathies:

Mutation search

Select locus:		Select mutation:

More Fewer search options

General information for Palestine

Palestine

Continent:	Asia
Capital:
Population:	3800000
Area (in sq km):	5970.0

Haemoglobinopathy-specific healthcare policy information for Palestine

Healthcare policy		Comment/Info	Reference
Prevention programme:	Yes (Regional)	Based on premarital screening, implemented in Palestinian West Bank and Gaza-Strip in 2000.	[PMID: 23224852]
SCD newborn screening:	No	From: 2nd MEGMA Conference Proceedings.
Prenatal screening:	No		[PMID: 11773575]
Antenatal screening:	Yes (National)	Mainly for suspected cases or families with a history of disease. From: 2011 WHO Report WHO-EM/NCD/068/E.
Patient associations:	Yes (National)	E.g.: Thalassaemia Patients Friends Society (TPFS Palestine).
Genetic counselling:	Yes (Regional)	As part of the prevention programme.	[PMID: 29751732]

Prevalence and incidence of major haemoglobinopathies in Palestine

Haemoglobinopathy		Reference
Prevalence of β-thalassaemia carriers:	4.3 % of the population	[PMID: 23224852]
Expected incidence of β-thalassaemia:	59 expected affected births/year	[PMID: 24672827]
Expected incidence of sickle cell disease:	45 expected affected births/year	[PMID: 24672827]
Known β-thalassaemia patients:	688 patients	[PMID: 24672827]
Known sickle cell disease patients:	131 patients	[PMID: 24672827]

Global Burden of Disease data for Palestine

Migration data for Palestine

Mutation frequencies in Palestine

Overview (most frequent mutations with their observed average values and range)

β-locus

IVS I-6 (T>C): 35.55 % (9 % – 76.5 %)	IVS I-110 G>A: 20.32 % (7.8 % – 33.9 %)
IVS I-1 G>A: 13.62 % (2 % – 31.5 %)	CD 6 GAG>GTG [Glu>Val] (HbS): 10.03 % (0.7 % – 25 %)

Detailed mutation frequencies

Entry ID	Locus	Region	Ethnic Group	Population Type	Sample Size	Study period (from)	Study period (to)	Reference	Comments
17573	β-locus	West Bank	Palestinian	Patients	102	2016	2017	30820323	Frequencies are shown for beta-globin gene mutations. Patients were diagnosed with beta-thalassaemia intermedia.
17574	β-locus	West Bank	Palestinian	Patients	32		2020	32420772	Frequencies are shown for beta-globin gene mutations. Patients with transfusion-dependent anaemia registered at the Thalassemia Patient Friends Society in Nablus governate.
17575	β-locus	Gaza Strip	Palestinian	Carriers and Patients	274		2013	23321370	Frequencies are shown for beta-globin gene mutations from both carriers and patients living in the Gaza Strip.
17576	β-locus	West Bank	Palestinian	Carriers and Patients	136		2002	11939510	Frequencies are shown for beta-globin gene mutations from both carriers and patients living in the southern part of the West Bank region of Palestine.
17577	β-locus	West Bank	Palestinian	Patients	279		2005	15921164	Frequencies are shown for beta-globin gene mutations from patients (thalassaemia major and intermedia) living in the West Bank region of Palestine.
17578	β-locus	Gaza Strip	Palestinian	Patients	164		2017	28670942	Frequencies are shown for beta-globin gene mutations.

Organisations in Palestine

Organisations in Palestine are currently not available

Microattributions

No microattibutions were provided for Palestine. Please contact us, if you are willing to review existing information or provide new data.

To provide new epidemiological information and/or report mistakes, please register/log in first or use the Contact Us form.

Important Note: The relative allele frequencies presented in IthaMaps are not calculated by ITHANET, but they are extracted from the corresponding publications. ITHANET is not responsible for any mistakes in the data. Please use this information with caution! We encourage scientists that have more detailed or updated epidemiological information to contact us.

Disclaimer: The information on this website is provided as an information resource only and must not to be used as a substitute for professional diagnosis and treatment. The ITHANET Portal and IthaMaps are not responsible or liable for any advice, course of treatment, diagnosis or any other information, services or products that an individual obtains through this website.

Note: The information you provide for the specific country will appear on the IthaMaps website and your contribution will be acknowledged.

Country:

Contributor's details

To be included in ITHANET Organisations & Experts

Name:		Organisation's name:
Surname:		Organisation's brief description:
Title:		Organisation's address:
Expertise/Research interests:		Organisation's City:
Address:		Organisation's Country:
City:		Organisation's website:
Country:		E-mail:
ORCID

Healthcare Policies

Health-policy	Select one Answer	Comment
Prevention programme
SCD newborn screening
Prenatal screening
Antenatal screening
Haemoglobinopathies patient registry
Rare disease patient registry
Dedicated treatment centres
Blood transfusion availability
Iron chelation availability
MRI facilities
Patient associations
Genetic counselling

Status of major Haemoglobinopathies

In Expected Incidence of β-thalassaemia and sickle cell disease please provide the number of expected affected births/year (without prevention).
In Incidence of β-thalassaemia and sickle cell disease please provide the number of affected births/year (after prevention).

Haemoglobinopathy	Provide value		Comment
Prevalence of β-thalassaemia carriers		% of the population
Prevalence of sickle cell disease carriers		% of the population
Prevalence of α-thalassaemia carriers		% of the population
Prevalence of Hb E carriers		% of the population
Prevalence of Hb C carriers		% of the population
Expected incidence of β-thalassaemia		expected affected births/year
Expected incidence of sickle cell disease		expected affected births/year
Expected incidence of α-thalassaemia		expected affected births/year
Incidence of β-thalassaemia		affected births/year
Incidence of sickle cell disease		affected births/year
Incidence of α-thalassaemia		affected births/year
Known β-thalassaemia patients		patients
Known sickle cell disease patients		patients

Mutation Frequencies

Please provide details about publications reporting mutation frequencies in the country of reference (either country-wide studies or region-specific studies).

Show on map:		Information to display:
Minimum sample size: